[조사자료] 글로벌 망막 정맥 폐쇄증 치료 시장 (2023-2030) : 소매 약국, 병원 및 진료소

■ 영문 제목 : Retinal Vein Occlusion Treatment Market Size, Share & Trends Analysis Report By End-user (Retail Pharmacy, Hospital & Clinics), By Disease Type (CRVO, BRVO), By Treatment (Anti-VEGF, Corticosteroid Drugs), By Region, And Segment Forecasts, 2023 - 2030
	■ 상품코드 : GRV23NOV283 ■ 조사/발행회사 : Grand View Research ■ 발행일 : 2023년 9월 ■ 페이지수 : 180 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (납기:3일) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의약품

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1인 열람용)	USD5,950 ⇒환산￦8,032,500	견적의뢰/주문/질문
Multi User (5인 열람용)	USD6,950 ⇒환산￦9,382,500	견적의뢰/주문/질문
Global/corporate License (기업 열람용)	USD8,950 ⇒환산￦12,082,500	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 망막 정맥 폐쇄증 치료 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 망막 정맥 폐쇄증 치료 시장 규모는 2030년까지 4. 18억 달러에 달할 것으로 예상되며, 2023년부터 2030년까지 6. 92%의 CAGR을 기록할 것으로 예측됩니다. 안과 질환의 유병률 증가, 노인 인구 증가, 안과 질환 치료에 대한 인식 증가가 시장 성장을 촉진하는 주요 요인입니다. 기존 제품 및 승인된 제품의 존재와 강력한 제품 파이프라인은 시장 성장을 촉진할 것으로 예상되는 요인입니다. 또한, 당뇨병과 죽상 동맥 경화증의 유병률 증가는 RVO의 유병률을 증가시켜 연구 기간 동안 시장에 긍정적인 영향을 미칠 수 있으며, RVO에 대한 신약 승인의 증가는 연구 기간 동안 시장에 유리한 기회를 제공 할 것으로 예상됩니다.

삼성바이오에피스는 황반부종, 신생혈관성 노인성 황반변성, 근시성 맥락막 신생혈관, RVO 등 망막질환 치료제인 바이오시밀러 의약품 비보비스(라니비주맙 누나)를 개발했으며, 2020년 9월 FDA로부터 시판 허가를 획득했습니다. 그러나 약물과 관련된 높은 비용이 약물 처방을 제한하고 시장 성장을 저해할 수 있으며, BMC Ophthalmology에 게재된 2021년 연구에 따르면, 라니비주맙으로 중심성 RVO(CRVO) 및 분지형 RVO(BRVO)를 치료하는 데 있어 중국에서는 품질 조정된 생존기간(QALY) 당 약 449. 17달러와 454. 75달러의 비용이 소요됩니다. 따라서, 높은 효능과 안전성을 갖춘 저렴한 가격의 의약품이 등장하면 예측 기간 동안 시장에 새로운 성장 기회를 제공할 것으로 예상됩니다.

또한, 당뇨병성 망막증, 백내장, 녹내장, 노인성 황반변성 등의 질환이 전 세계적으로 이 질환의 주요 원인이 되고 있습니다. 노인 인구가 증가함에 따라 RVO 환자 수도 비례하여 증가하고 있습니다. 또한, 생활습관의 변화로 인해 심혈관 질환, 고혈압 등 RVO를 유발하는 다양한 질환의 발생률도 증가하고 있습니다. 랜싯 글로벌 보건위원회(Lancet Global Health Commission)의 세계 눈 건강 보고서에 따르면, 2020년에는 전 세계 5억 1,000만 명이 교정되지 않은 근거리 시력 장애를, 5억 9,600만 명이 교정되지 않은 원거리 시력 장애를 있을 것으로 추정되고 있습니다. 이러한 이차적 질환의 유병률 증가는 RVO의 유병률을 증가시켜 시장 성장을 뒷받침할 수 있습니다.

망막 정맥 폐쇄증 치료 시장 보고서 하이라이트

- 질병 유형별로는 효율적인 치료를 위한 연구개발 활동과 신약 개발에 대한 투자가 증가함에 따라 2022년에는 분지 부문이 시장을 주도할 것으로 예상됩니다.

- 치료제별로는 항혈관내피성장인자(anti-VEGF) 분야가 안전성과 1차 선택약물로서의 보편적 수용성으로 인해 2022년 가장 큰 점유율을 차지할 것으로 예상됩니다.

- 소매 약국의 RVO 치료제의 접근성 향상과 선택 가능성과 같은 요인으로 인해 소매 약국 최종 사용자 부문이 2022년 가장 큰 점유율을 차지할 것으로 예상됩니다.

- 북미는 2022년 41. 2%의 점유율을 차지하며 지역별로 확고한 입지를 구축했습니다. 이는 이 지역의 정부 보조금 증가로 인한 광범위한 R&D 활동과 높은 치료법 채택률에 기인한다고 전했습니다.

■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변동, 동향, 범위
Chapter 4. 세계의 망막 정맥 폐쇄증 치료 시장 : 질환 유형별 예측 및 동향 분석
Chapter 5. 세계의 망막 정맥 폐쇄증 치료 시장 : 치료별 예측 및 동향 분석
Chapter 6. 세계의 망막 정맥 폐쇄증 치료 시장 : 최종 용도별 예측 및 동향 분석
Chapter 7. 세계의 망막 정맥 폐쇄증 치료 시장 : 지역별 예측 및 동향 분석
Chapter 8. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective – 1
1.2.2. Objective – 2
1.2.3. Objective – 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Disease Type and Treatment Snapshot
2.3. End-user Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Increasing prevalence of retinal diseases
3.4.2. Rising geriatric population
3.4.3. Presence of strong product portfolio
3.5. Market Restraint Analysis
3.5.1. Lack of awareness and underdiagnoses of the disease
3.5.2. High cost of the treatment
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Disease Type Business Analysis
4.1. Retinal Vein Occlusion Treatment market: Disease Type Movement Analysis
4.2. Central Retinal Vein Occlusion (CRVO)
4.2.1. Central Retinal Vein Occlusion (CRVO) Market, 2018 – 2030 (USD Million)
4.3. Branch Retinal Vein Occlusion (BRVO)
4.3.1. Branch Retinal Vein Occlusion (BRVO) Market, 2018 – 2030 (USD Million)
Chapter 5. Treatment Business Analysis
5.1. Retinal Vein Occlusion Treatment Market: Treatment Movement Analysis
5.2. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
5.2.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Market, 2018 – 2030 (USD Million)
5.3. Corticosteroid Drugs
5.3.1. Corticosteroid Drugs Market, 2018 – 2030 (USD Million)
5.4. Others
5.4.1. Others Market, 2018 – 2030 (USD Million)
Chapter 6. End-user Business Analysis
6.1. Retinal Vein Occlusion Treatment Market: End-user Movement Analysis
6.2. Hospital & Clinics
6.2.1. Hospital & Clinics Market, 2018 – 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market, 2018 – 2030 (USD Million)
6.4. Others
6.4.1. Others Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Retinal Vein Occlusion Treatment Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Competitive Scenario
7.2.2.4. Regulatory Framework
7.2.2.5. Reimbursement Scenario
7.2.2.6. U.S. Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD MILLION)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. Canada Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. Europe Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3.2. Germany
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. Reimbursement Scenario
7.3.2.6. Germany Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. UK Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. France Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. Italy Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Spain Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Denmark Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Sweden Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Norway Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Reimbursement Scenario
7.4.2.6. Japan Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. China Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. India Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. South Korea Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. Australia Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Thailand Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Competitive Scenario
7.5.2.4. Regulatory Framework
7.5.2.5. Reimbursement Scenario
7.5.2.6. Brazil Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Mexico Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Scenario
7.5.4.6. Argentina Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. MEA Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Competitive Scenario
7.6.2.4. Regulatory Framework
7.6.2.5. Reimbursement Scenario
7.6.2.6. South Africa Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. Saudi Arabia Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. UAE Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. Kuwait Retinal Vein Occlusion Treatment market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant’s overview
8.2. Financial performance
8.3. Participant categorization
8.3.1. Market Leaders
8.3.2. Retinal Vein Occlusion Treatment market Share Analysis, 2022
8.3.3. Company Profiles
8.3.3.1. AbbVie Inc
8.3.3.1.1. Company Overview
8.3.3.1.2. Financial Performance
8.3.3.1.3. Product Benchmarking
8.3.3.1.4. Strategic Initiatives
8.3.3.2. F. Hoffmann-La Roche Ltd
8.3.3.2.1. Company Overview
8.3.3.2.2. Financial Performance
8.3.3.2.3. Product Benchmarking
8.3.3.2.4. Strategic Initiatives
8.3.3.3. Regeneron Pharmaceuticals Inc
8.3.3.3.1. Company Overview
8.3.3.3.2. Financial Performance
8.3.3.3.3. Product Benchmarking
8.3.3.3.4. Strategic Initiatives
8.3.3.4. Taiwan Liposome Company, Ltd
8.3.3.4.1. Company Overview
8.3.3.4.2. Financial Performance
8.3.3.4.3. Product Benchmarking
8.3.3.4.4. Strategic Initiatives
8.3.3.5. Aerie Pharmaceuticals Inc
8.3.3.5.1. Company Overview
8.3.3.5.2. Financial Performance
8.3.3.5.3. Product Benchmarking
8.3.3.5.4. Strategic Initiatives
8.3.3.6. CalciMedica Inc
8.3.3.6.1. Company Overview
8.3.3.6.2. Financial Performance
8.3.3.6.3. Product Benchmarking
8.3.3.6.4. Strategic Initiatives
8.3.3.7. Outlook Therapeutics, Inc
8.3.3.7.1. Company Overview
8.3.3.7.2. Financial Performance
8.3.3.7.3. Product Benchmarking
8.3.3.7.4. Strategic Initiatives
8.3.3.8. Kodiak Sciences Inc
8.3.3.8.1. Company Overview
8.3.3.8.2. Financial Performance
8.3.3.8.3. Product Benchmarking
8.3.3.8.4. Strategic Initiatives
8.3.3.9. Chugai Pharmaceutical Co., Ltd
8.3.3.9.1. Company Overview
8.3.3.9.2. Financial Performance
8.3.3.9.3. Product Benchmarking
8.3.3.9.4. Strategic Initiatives
8.3.3.10. Pfizer Inc
8.3.3.10.1. Company Overview
8.3.3.10.2. Financial Performance
8.3.3.10.3. Product Benchmarking
8.3.3.10.4. Strategic Initiatives
8.3.4. Strategy Mapping
8.3.4.1. Expansion
8.3.4.2. Acquisition
8.3.4.3. Collaborations
8.3.4.4. Disease Type/Drug Class Launch
8.3.4.5. Partnerships
8.3.4.6. Others

List of Tables

Table 1 List of Abbreviations
Table 2 Global Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 3 Global Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 4 Global Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 5 Global Retinal Vein Occlusion Treatment Market, by Region, 2018 - 2030 (USD Million)
Table 6 North America Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 7 North America Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 8 North America Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 9 North America Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 10 U.S. Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 11 U.S. Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 12 U.S. Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 13 Canada Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 14 Canada Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 15 Canada Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 16 Europe Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 17 Europe Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 18 Europe Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 19 Europe Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 20 Germany Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 21 Germany Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 22 Germany Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 23 UK Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 24 UK Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 25 UK Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 26 France Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 27 France Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 28 France Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 29 Italy Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 30 Italy Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 31 Italy Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 32 Spain Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 33 Spain Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 34 Spain Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 35 Denmark Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 36 Denmark Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 37 Denmark Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 38 Sweden Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 39 Sweden Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 40 Sweden Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 41 Norway Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 42 Norway Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 43 Norway Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 48 China Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 49 China Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 50 China Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 51 Japan Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 52 Japan Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 53 Japan Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 54 India Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 55 India Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 56 India Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 57 South Korea Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 58 South Korea Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 59 South Korea Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 60 Australia Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 61 Australia Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 62 Australia Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 63 Thailand Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 64 Thailand Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 65 Thailand Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 66 Latin America Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 67 Latin America Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 68 Latin America Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 69 Latin America Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 70 Brazil Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 71 Brazil Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 72 Brazil Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 73 Mexico Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 74 Mexico Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 75 Mexico Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 76 Argentina Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 77 Argentina Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 78 Argentina Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 83 South Africa Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 84 South Africa Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 85 South Africa Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 89 UAE Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 90 UAE Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 91 UAE Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
Table 92 Kuwait Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
Table 93 Kuwait Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 94 Kuwait Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)

※본 조사보고서 [글로벌 망막 정맥 폐쇄증 치료 시장 (2023-2030) : 소매 약국, 병원 및 진료소] (코드 : GRV23NOV283) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 망막 정맥 폐쇄증 치료 시장 (2023-2030) : 소매 약국, 병원 및 진료소] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 펩티드 마이크로어레이 시장 (2023~2030) : 질환 진단, 단백질 기능 분석
GRV23MA024 / Grand View Research / 2023년 1월 / 미국 Grand View Research (그랜드뷰리서치)는 세계의 펩티드 마이크로어레이 시장 규모가 2023년부터 2030년 사이에 연평균 4.51% 성장하여, 2030년에는 1,133.5백만 달러에 달할 것으로 예측하고 있습니다. 본 조사 자료는 세계의 펩티드 마이크로어레이 시장을...Peptide Microarray Market Growth & Trends The global peptide microarray market size is expected to reach USD 1,133.5 million by 2030, registering a CAGR of 4.51% over the forecast period, according to a new report by Grand View Research, Inc. The market is expected to witness a stable growth rate...

세계의 라벨 프리 어레이 시스템 시장 (2023~2030) : 표면 플라즈몬 공명, 생체층 간섭, 세포 유전 분광
GRV23MR110 / Grand View Research / 2023년 2월 / 미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 라벨 프리 어레이 시스템 시장 규모가 2023년부터 2030년 사이에 CAGR 7.42% 증가하여, 2030년에는 799.59백만 달러에 이를 것으로 예상하고 있습니다. 본 자료는...Label-free Array System Market Growth & Trends The global label-free array system market size is expected to reach USD 799.59 million by 2030, expanding at a CAGR of 7.42% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness substantial...

글로벌 항바이러스제 시장 (2023-2030) : 브랜드, 제네릭
GRV23NOV002 / Grand View Research / 2023년 9월 / 글로벌 항바이러스제 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 항바이러스제 시장 규모는 2023년부터 2030년까지 연평균 성장률 -1. 99%를 기록하며 2030년까지 620. 5억 달러에 달할 것으로 예상됩니다. 이러한...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변수/동향/범위 Chapter 4. 세계의 항바이러스제 시장 : 유형별 분석 Chapter 5. 세계의 항바이러스제 시장 : 약품 종류별 분석 Chapter 6. 세계의 항바이러스제 시장 : 유통 채널별 분석 Chapter 7. 세계의 항바이러스제 시장 : 용도별 분석 Chapter 8. 세계의...

세계의 맞춤형 항체 시장 (2023~2030) : 단클론 항체, 폴리클로날 항체, 재조합 항체, 기타
GRV23MR076 / Grand View Research / 2023년 2월 / 미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 맞춤형 항체 시장 규모가 2023년부터 2030년 사이에 CAGR 9.7% 증가하여, 2030년에는 301.7백만 달러에 이를 것으로 예상하고 있습니다. 본 자료는 세계의 맞춤형...Custom Antibody Market Growth & Trends The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness substantial growth during...

세계의 미생물 API 시장 2023-2030 : 호스별 (포유류, 박테리아, 곰팡이), 유형별 (항체, 펩타이드, 단백질), 부위별, 분자별, 최종 용도별, 지역별
GRV24JAN164 / Grand View Research / 2023년 11월 / 글로벌 미생물 API 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 미생물 API 시장 규모는 2030년까지 961억1000만 달러에 달할 것으로 예상되며, 2023년에서 2030년까지 6.66%의 CAGR을 기록할 것으로...1. 조사 방법 및 범위 2. 개요 3. 세계의 미생물 API 시장 변수/동향/범위 4. 세계의 미생물 API 시장 규모 : 호스트별 비즈니스 분석 5. 세계의 미생물 API 시장 규모 : 유형별 비즈니스 분석 6. 세계의 미생물 API 시장 규모 : 사이트별 비즈니스 분석 7. 세계의 미생물 API 시장 규모 :...